Merck & Co.’s immunotherapy Keytruda keeps winning approvals for new indications. Indeed, it was yesterday approved in Europe, in combination with chemotherapy, for non-small-cell lung cancer (NSCLC). Keytruda is the first inhibitor of PD-1 receptors to be approved for NSCLC, both as monotherapy and in combination with chemotherapy. The approval reflects the positive results achieved in the KEYNOTE-189 clinical trial, in which Keytruda demonstrated superiority versus chemotherapy. Merck & Co.’s shares today have increased over 20% YTD (Wall Street), reaching a record $184bn capitalization.
(Source: Merck & Co.)